Mostra i principali dati dell'item

dc.contributor.authorLlamas Ramos, Inés 
dc.contributor.authorLlamas Ramos, Rocío 
dc.contributor.authorCarrillo González, Gloria Mabel
dc.contributor.authorSepúlveda Ramírez, Jennifer
dc.contributor.authorVargas Rosero, Elizabeth
dc.date.accessioned2024-11-11T18:26:41Z
dc.date.available2024-11-11T18:26:41Z
dc.date.issued2022
dc.identifier.citationLlamas-Ramos, I.; Llamas-Ramos, R.; Carrillo-González, G.M.; Sepúlveda-Ramírez, J.; Vargas-Rosero, E. Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS. Cancers 2022, 14, 1624. https://doi.org/10.3390/cancers14071624es_ES
dc.identifier.urihttp://hdl.handle.net/10366/160598
dc.description.abstractCancer patients experience several symptoms throughout their illness and the treatments they receive. While this pathology represents a worldwide health problem, knowing the symptom prevalence in oncology patients remains a challenge; validated tools to obtain this information are essential. Furthermore, this prevalence information would help health professionals to establish appropriate treatments. The objective of this study was to ascertain the symptom prevalence in cancer patients from Spain and Colombia to improve future approaches. The frequency, severity, and distress of 32 symptoms from a validated scale experienced by cancer patients from Spain and Colombia were measured. Two hundred and forty-six patients (49.7%) who attended the Day University Hospital of Salamanca (Spain) and two hundred and forty-nine outpatients (50.3%) of the San Diego Cancer Center (Colombia) between 2016 and 2019 participated in the study. All patients filled in the Assessment Scale only once. Four hundred and ninety-five patients (333 women (67.3%) and 162 men (32.7%)) completed the Memorial Symptom Assessment Scale (Spanish version). The most frequent symptom for both samples (Spanish and Colombian) was “lack of energy” (38.4% and 13.7%, respectively). The most severe symptoms for the Spanish and Colombian samples were “problems with sexual interest or activity” (38.4%) and “dry mouth” (13.7%), respectively, and both samples agreed on the most distressing symptom: “hair loss” (Spanish, 38%; Colombian, 10.1%). The Spanish version of the MSAS has proven to be a valid and reliable tool in Spanish-speaking countries to obtain the most prevalent, severe, and distressing symptoms in Spanish and Colombian oncology patients. The prevalence of symptoms was demonstrated to be similar across both countries, and the results will help to design and adapt treatments for cancer patients, targeting these symptoms to reduce or avoid them and thus improving their quality of life.es_ES
dc.language.isoenges_ES
dc.publisherhttps://www.mdpi.com/2072-6694/14/7/1624es_ES
dc.subjectColombiaes_ES
dc.subjectSpaines_ES
dc.subjectCanceres_ES
dc.subjectPrevalencees_ES
dc.subjectReliabilityes_ES
dc.subjectSymptomes_ES
dc.subject.meshPrevalence *
dc.titleSymptom prevalence in spanish and colombian oncology patients measured with the MSASes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.3390/cancers14071624es_ES
dc.identifier.doi10.3390/cancers14071624
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn2072-6694
dc.journal.titleCancerses_ES
dc.volume.number14es_ES
dc.issue.number7es_ES
dc.page.initial1624es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsprevalencia *
dc.subject.decssíntomas *


Files in questo item

Thumbnail

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item